LICENSE AND RESEARCH AGREEMENT (Amended and Restated)Exclusive License Agreement • November 13th, 2001 • Rigel Pharmaceuticals Inc • Pharmaceutical preparations • California
This License And Research Agreement (the “Agreement”) is made and entered into as of September 2, 1999, (the “Effective Date”), as first amended and restated on March 26, 2001 and again amended and restated on July 1, 2001 (the “Restatement Date”), by and between Rigel Pharmaceuticals, Inc., a corporation organized under the laws of Delaware and having a principal place of business at 240 East Grand Avenue, South San Francisco, CA 94080 (“Rigel”) and Cell Genesys, Inc., a corporation organized under the laws of Delaware and having a principal place of business at 342 Lakeside Drive, Foster City, CA 94404 (“CG”). Rigel and CG may be referred to collectively as the “Parties,” or individually as a “Party.”
SECOND AMENDMENT TOCollaboration Agreement • November 13th, 2001 • Rigel Pharmaceuticals Inc • Pharmaceutical preparations
This Second Amendment to Collaboration Agreement (“Amendment”) is entered into as of July 6, 2001 (“Amendment Date”) by and between Rigel Pharmaceuticals, Inc., a Delaware corporation (“Rigel”) having offices at 240 East Grand Avenue, South San Francisco, CA 94080, and Novartis Pharma AG, a Swiss corporation (“Novartis”) having offices at Lichtstrasse 35, CH-4058, Basel, Switzerland. Rigel and Novartis are referred to herein collectively as the “Parties,” and each individually as a “Party.”
